

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 16/28, C12N 15/13, 15/63, A61K 39/395</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/31141</b> <b>(43) International Publication Date:</b> 2 June 2000 (02.06.00)
<b>(21) International Application Number:</b> PCT/KR99/00699 <b>(22) International Filing Date:</b> 19 November 1999 (19.11.99)  <b>(30) Priority Data:</b> 1998/49663      19 November 1998 (19.11.98)      KR  <b>(71) Applicants (for all designated States except US):</b> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY [KR/KR]; 39-1 Hawolgok-dong, Sungbuk-ku, Seoul 136-130 (KR). KOREA GREEN CROSS CORPORATION [KR/KR]; 227 Gugal-ri, Kiheung-eup, Yongin-si, Kyonggido 449-900 (KR).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HONG, Hyo, Jeong [KR/KR]; #15-401 Kit Apt., 237 Kajeong-dong, Eusong-ku, Taejon-si 305-350 (KR). RYU, Chun, Jeih [KR/KR]; #136-1203 Hanbit Apt., 99 Oeun-dong, Eusong-ku, Taejon-si 305-333 (KR). HUR, Hyangsuk [KR/KR]; #106-1508 Expo Apt., Jeonmin-dong, Eusong-ku, Taejon-si 305-390 (KR).  <b>(74) Agent:</b> LEE, Won-Hee; Suite 805, Sung-ji Heights II, 642-16 Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND PREPARATION METHOD THEREOF  <b>(57) Abstract</b>  The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1, which show binding affinity similar to mouse monoclonal antibody and which show remarkably reduced immunogenicity since they have less mouse-derived amino acid residues. Thus, the humanized antibodies of the present invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1  
OF HBV AND PREPARATION METHOD THEREOF

FIELD OF THE INVENTION

5           The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1.

          Particularly, this invention relates to humanized antibodies specific for HBV surface antigen pre-S1, the antibody comprising humanized heavy and light chain; to  
10          genes encoding the humanized heavy or light chain; to expression vectors containing said genes and *E. coli* transformants containing said expression vector; and to pharmaceutical composition comprising said humanized  
15          antibody, which may be administered in order to prevent HBV infection or to treat chronic hepatitis B.

BACKGROUND

          HBV (Hepatitis B Virus) is responsible for chronic or acute human hepatitis that may get worse to liver  
20          cirrhosis or cancer. It is estimated that about three hundred million people are suffering from hepatitis in the world (Tiollais and Buendia, *Sci. Am.* 264:48, 1991).

          There are three kinds of HBV surface proteins containing different sets of surface antigens.  
25          Particularly, these surface antigen proteins includes the Major Protein containing S antigen, the Middle

Protein containing S and pre-S2 antigens, and the Large Protein containing S, pre-S2 and pre-S1 antigens (Neurath and Kent, *Adv. Virus Res.*, 34:65-142, 1988). All the surface antigen proteins can induce antibodies  
5 that neutralize HBV, and especially, antibodies against HBV pre-S antigen are associated with the elimination of the virus and the recovery from HBV infection, overcoming non-responsiveness to the S antigen (Iwarson et al., *J. Med. Virol.*, 16:89-96, 1985; Itoh et al.,  
10 *Proc. Natl. Acad. Sci. USA*, 85:9174-9178, 1986; Budkowska et al., *J. Med. Virol.*, 20:111-125, 1986; Milich et al., *Proc. Natl. Acad. Sci. USA*, 82:8168-8172, 1985; Milich et al., *J. Immunol.*, 137:315-322, 1986).

Unlike pre-S2 or S antigen, pre-S1 antigen is  
15 exclusively present in infectious virus particles (Heerman et al., *J. Virol.*, 52:396-402, 1984) and involved in the infection into human liver cells. Thus, it has been reported that monoclonal antibody specific for pre-S1 antigen may efficiently neutralize HBV  
20 (Neurath et al., *Cell*, 46:429, 1986; Pontisso et al., *Virology*, 173:533, 1989; Neurath et al., *Vaccine*, 7:234, 1989), and the monoclonal antibody is considered to be useful in the prevention of HBV infection and the treatment of chronic hepatitis B.

25

So far hepatitis B immunoglobulin has been employed as a preventive for HBV infection, which may

protect, for example, a newborn baby from a HBV-positive mother, medical personnel exposed to HBV, and liver transplant patient with chronic HBV-related liver disease (Beasley et al., *Lancet*, 2:1099, 1983; Todo et al., *Hepatology*, 13:619, 1991). However, hepatitis B immunoglobulin has some shortcomings such as its limited availability, low specific activity and its possible contamination with infectious agents. Furthermore, it is another disadvantage of hepatitis B immunoglobulin that blood plasma should be continuously supplied.

As an alternative for the hepatitis B immunoglobulin, mouse monoclonal antibodies against HBV surface antigens have been developed. Although the mouse monoclonal antibodies show high affinity for the antigen and can be prepared on a large scale, they induce human anti-mouse antibody response in patients (Shawler et al., *J. Immunol.*, 135:1530, 1985). There were attempts to prepare human monoclonal antibodies, but few of these antibodies showed a high level of affinity.

Instead, humanized antibodies have been developed. Humanized antibody has a high level of affinity and specificity similar to mouse antibodies, whereas its immunogenicity is minimized. Humanized antibody is a hybrid antibody in which CDRs (Complementarity Determining Regions) of a mouse antibody is grafted to

a human antibody by genetic engineering technique. It can be easily prepared on a large scale, and hardly elicits immune responses in humans since most of the DNA sequences encoding the humanized antibodies are  
5 derived from a human DNA sequence (Riechman et al., *Nature*, 332:323, 1988; Nakatani et al., *Protein Engineering*, 7:435, 1994).

To overcome the aforementioned and other  
10 disadvantages of mouse or human HBV immunoglobulin, we, the inventors of the present invention, have attempted to prepare humanized antibodies which can be used to prevent HBV infection and to treat chronic hepatitis B. Prior to this invention, we prepared a mouse monoclonal  
15 antibody KR127 against HBV surface antigen pre-S1. Additionally, we isolated the genes encoding the heavy and light chain variable regions of KR127 antibody and determined the sequences of the genes (Korea Patent Application No. 1997-30696). The present invention is  
20 performed by selecting human immunoglobulin genes homologous to the sequences of KR127 antibody light chain and heavy chain variable regions; constructing the humanized antibody genes; inserting the genes into expression vectors; introducing the vectors into host  
25 cells; obtaining humanized antibodies from the culture of the transformed cells; and confirming that the humanized antibodies have high affinity to HBV pre-S1

antigen, similar to the mouse monoclonal antibody KR127.

#### SUMMARY OF THE INVENTION

5 It is an object of this invention to provide humanized antibodies specific for CDRs of mouse HBV surface antigen pre-S1, having high affinity to the antigen and reduced immunogenicity in human.

10 In accordance with the present invention, the foregoing objects and advantages are readily obtained.

The present invention provides humanized antibodies specific for HBV surface antigen pre-S1, comprising humanized heavy and light chains.

15 This invention also provides genes encoding the variable regions of said humanized heavy or light chain.

In addition, this invention provides expression vectors containing said genes and *E. coli* transformants containing said expression vectors.

20 This invention further provides pharmaceutical compositions comprising said humanized antibody, which may be administered in order to prevent HBV infection or to treat chronic hepatitis B.

Further features of the present invention will appear hereinafter.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIG 1a and FIG 1b comparatively depict the amino acid and nucleotide sequences of  $V_H$  regions (for Variable regions of Heavy chains) in a mouse monoclonal antibody KR127 and in two humanized antibodies of this invention,

FIG 2a schematically depicts a process for preparing HKR127HC(I) gene encoding the heavy chain of a humanized antibody of this invention,

10 FIG 2b schematically depicts a process for preparing HKR127HC(III) gene encoding the heavy chain of a humanized antibody of this invention,

FIG 3a and FIG 3b comparatively depict the amino acid and nucleotide sequences of  $V_L$  regions (for Variable regions in Light chain) in a mouse monoclonal antibody KR127 and in a humanized antibody of this invention.

FIG 4 schematically depicts a process for preparing HKR127KC(I) gene encoding a humanized antibody of this invention,

FIG 5a depicts an expression vector pCMV-HKR127HC containing a gene for heavy chain of the humanized antibody,

FIG 5b depicts an expression vector pKC-dhfr-HKR127 containing a gene for light chain of the humanized antibody,



FIG 5c depicts an expression vector pCMV-HKR127HC(III) containing a gene for heavy chain of the humanized antibody,

FIG 6a comparatively shows the binding affinities of a humanized antibody (HZKR127I) and a mouse monoclonal antibody (KR127), and

FIG 6b comparatively shows the binding affinities of a humanized antibody (HZKR127III) and a humanized antibody (HZKR127I).

10

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Hereinafter, the present invention is described in detail.

This invention provides humanized antibodies specific for HBV surface antigen pre-S1, comprising humanized heavy and humanized light chains.

This invention also provides genes encoding the variable regions of said humanized heavy or light chain.

Said humanized heavy chain contains variable region which is derived from the  $V_H$  region of mouse KR127 antibody. The  $V_H$  region of mouse KR127 antibody is described by SEQ ID NO: 19, and the  $V_H$  region of the humanized antibody of this invention can be prepared by grafting the CDRs of mouse KR127  $V_H$  region to homologous human immunoglobulin  $V_H$  region.

And said humanized light chain contains variable

region which is derived from the  $V_L$  region of mouse KR127 antibody. The  $V_L$  region of mouse KR127 antibody is described by SEQ ID NO: 22, and the  $V_L$  region of the humanized antibody of this invention can be prepared by  
5 grafting the CDRs of mouse KR127  $V_L$  region to homologous human immunoglobulin  $V_L$  region.

In preferred embodiments, we screened human immunoglobulin that show the highest similarities of amino acid sequence to the heavy or light chain of the  
10 mouse monoclonal antibody KR127. In result, human immunoglobulin germ line genes DP7 and DPK12 were screened from GenBank database. DP7 shows the highest homology to the  $V_H$  region of mouse antibody KR127, while DPK12 is most similar to the  $V_L$  region of KR127.

15 The humanized antibodies of this invention can be produced from recombinant genes encoding humanized  $V_H$  region or  $V_L$  region. These genes are constructed by substituting CDRs of mouse KR127 for those of the human DP7 or DPK12 antibody. In constructing these genes,  
20 most of the amino acid residues corresponding to the humanized CDRs are derived from the CDRs of mouse antibody KR127. However, some mouse-derived CDRs residues are replaced by human counterparts, since their corresponding amino acid residues are expected  
25 not to be involved in the antigen binding (see FIG 1). In the same way, some human-derived amino acid residues for the non-CDR framework regions (FR) of variable

region are replaced with mouse counterparts, since it is expected that these FR residues may affect the conformation of CDRs.

Particularly, HKR127HCv(HZII) gene encoding a humanized V<sub>H</sub> region was prepared by grafting the partial CDR1, 2, 3 and a FR residue (at position 72) of mouse KR127 heavy chain to the human DP7 gene (see FIG 1).

However, antibody expressed from HKR127HCv(HZII) gene did not show any significant level of binding capacity to corresponding antigen. To improve the HKR127HCv(HZII) gene, we also prepared HKR127HCv(HZI) gene and HKR127HCv(HZIII) gene which contain more mouse-derived codons than HKR127HCv(HZII) gene (see FIG 1).

HKR127HCv(HZI) contains CDR1, partial CDR2, and CDR3, and 11 FR residues of mouse KR127 V<sub>H</sub>, while HKR127HCv(HZIII) contains the same mouse CDR codons and 2 mouse FR residues (see FIG 1).

To construct HKR127HC(I) gene encoding a full-length heavy chain of the humanized antibody of this invention, PCRs were conducted, in which template for amplification is either the HKR127HCv(HZII) gene or pRC/CMV-HC-HuS (KCTC 0229BP) containing the heavy chain leader sequence and the constant region sequence of human immunoglobulin heavy chain  $\gamma$ 1.

Six pairs of oligonucleotides (SEQ ID NO: 1 and 2;

3 and 4; 5 and 6; 7 and 8; 9 and 10; and 11 and 12) were used as PCR primers (see FIG 2a).

The first five PCR products were brought to annealing reaction. Then, the DNA fragment containing the five PCR products was employed as a template of recombinant PCR wherein two primers described by SEQ ID NO: 1 and 10 were used. Another recombinant PCR was conducted to link the amplified 431-bp DNA fragment to DNA fragment which was obtained by PCR using two primers (described by SEQ ID NO: 11 and 12). The recombinant PCR employed two primers described by SEQ ID NO: 1 and 12. The final 1431-bp PCR product, HKR127HC(I), encoding the heavy chain of a humanized antibody (HZKR127I) was introduced into pBluescript SK(+) vector (Clontech), and the resulting vector was designated pHKR127HC(I).

The primers are described in SEQ ID NO: 1 to 12 in SEQUENCE LISTING, and particularly, primer described by SEQ ID NO: 1 contains EcoRI sequence at the 5' end, while primer described by SEQ ID NO: 12 does SalI sequence at the 3' end.

The variable region in the HKR127HC(I) gene contains 11 mouse-derived FR residues at positions 12, 28, 30, 48, 67, 68, 70, 72, 74, 79 and 95 (see FIG 1). The heavy chain variable region has 87 FR residues, and the unmodified FR residues is 76. Thus, the amino acid sequence of the heavy chain variable FR of the

HKR127HC(I) gene is 87% homologous to that of human DP7 gene.

To more humanize the HZKR127(I), HZKR127(III) gene was constructed, which contains HKR127HCv(HZIII) gene with 2 mouse-derived FR residues at position 72 and 74 (see FIG 1).

To construct HKR127HC(III) gene encoding a full-length heavy chain of the humanized antibody of this invention, PCRs were conducted, in which template for amplification is either the HKR127HCv(HZII) gene or pRC/CMV-HC-HuS (KCTC 0229BP) containing the heavy chain leader sequence and the constant region sequence of human immunoglobulin heavy chain  $\gamma 1$  (see FIG 2b).

Four pairs of oligonucleotides (SEQ ID NO: 1 and 24; 25 and 26; 27 and 28; and 11 and 12) were used as PCR primers (see FIG 2b). The first three PCR products were brought to annealing reaction. Then, the DNA fragment containing the three PCR products was employed as a template of recombinant PCR wherein two primers described by SEQ ID NO: 1 and 28 were used. Another recombinant PCR was conducted to link the amplified 431-bp DNA fragment to DNA fragment which was obtained by PCR using two primers (described by SEQ ID NO: 11 and 12). The recombinant PCR employed two primers described by SEQ ID NO: 1 and 12.

The final 1431-bp PCR product, HKR127HC(III), encoding the heavy chain of a humanized antibody

(HZKR127III) was introduced into pBluescript SK(+) vector (Clontech), and the resulting vector was designated pHKR127HC(III).

5           In a further embodiment, HKR127KcV(HZII) gene encoding a humanized V<sub>L</sub> region was prepared by grafting the CDR1, CDR3 and partial CDR2 of mouse KR127 light chain to the human DPK12 gene (see FIG 3).

          However, antibody expressed by using the  
10   HKR127KcV(HZII) gene did not show any significant level of binding capacity to corresponding antigen. To improve the binding capacity of HKR127KcV(HZII), we also prepared HKR127KcV(HZI) gene which contains more mouse-derived amino acid residues (see FIG 3) than  
15   HKR127HKcV(HZII) (see FIG 3).

          To construct HKR127Kc(I) gene encoding a full-length light chain of the humanized antibody of this invention, PCRs were conducted, in which template for amplification is either the HKR127KcV(HZII) gene or  
20   pKC-dfhr-HuS (KCTC 0230BP) containing the light chain leader sequence and the constant region sequence of human immunoglobulin light chain  $\kappa$ .

          Three pairs of oligonucleotides (SEQ ID NO: 13 and 14; 15 and 16; and 17 and 18) were used as PCR primers  
25   (see FIG 4).

          The first two PCR products were brought to annealing reaction. Then, the DNA fragment containing

the two PCR products was employed as a template of recombinant PCR wherein two primers described by SEQ ID NO: 13 and 16 were used. Another recombinant PCR was conducted to link the amplified 360-bp DNA fragment to DNA fragment which was obtained by PCR using two primers (described by SEQ ID NO: 17 and 18). The recombinant PCR employed two primers which are described by SEQ ID NO: 13 and 18. The final 739-bp PCR product, HKR127KC(I), encoding the light chain of a humanized antibody (HZKR127I) was introduced into pBluescript SK(+) vector (Clontech), and the resulting vector was designated pHKR127KC(I).

The primers are described in SEQ ID NO: 13 to 18 in SEQUENCE LISTING, and particularly, primer described by SEQ ID NO: 13 contains HindIII sequence at the 5' end, while primer described by SEQ ID NO: 18 does SalI sequence at the 3' end.

The variable region FR of the HKR127KC gene contains 5 mouse KR127-derived codons (see FIG 3). The light chain has 83 FR residues, and the unmodified FR residues is 78. Thus, the amino acid sequence of the light chain variable FR of the HKR127KC gene is 94% identical to that of human DP7 gene.

In addition, this invention provides expression vectors containing genes encoding the humanized  $V_H$  or  $V_L$  region and provides *E. coli* transformants containing

said expression vector.

In other preferred embodiments, expression vectors are prepared, which contain the gene encoding the heavy or light chain of humanized antibody (see FIG 5a, 5b or  
5 5c).

Particularly, two kinds of DNA fragment corresponding to humanized heavy chain was respectively obtained from the plasmids pHKR127HC(I) and pHKR127HC(III) by treatment of restriction enzymes, and  
10 then inserted into pRc/CMV (Invitrogen) to give expression vector pCMV-HKR127HC (see FIG5a) and pCMV-HKR127(III)HC (see FIG 5c), respectively.

In addition, DNA fragment encoding the humanized light chain was isolated from the pHKR127KC vector, and  
15 then introduced into pCMV-dhfr (KCTC 8671P) to construct expression vector pKC-dhfr-HKR127 (see FIG 5b).

*E. coli* strain DH5 $\alpha$  was transformed with the expression vector pCMV-HKR127HC, pCMV-HKR127(III)HC or  
20 pKC-dhfr-HKR127. The resulting *E. coli* transformants containing pCMV-HKR127HC or pKC-dhfr-HKR127 were deposited in KCTC (Korean Collection for Type Culture) (Accession Number: KCTC 0531BP and KCTC 0529BP, respectively) on October 12, 1998. The *E. coli*  
25 transformant containing pCMV-HKR127(III)HC was deposited in KCTC (Accession Number: KCTC 0691BP, respectively) on November 15, 1999.



In another preferred embodiment, humanized antibodies specific for HBV surface antigen pre-S1 were expressed in animal cells and obtained from culture media of the cells. COS7 cells were transiently cotransfected with the expression vectors pCMV-HKR127HC and pKC-dhfr-HKR127, and the resulting transfected cells was cultured and the culture supernatant was used to characterize a humanized antibody HZKR127I of the present invention. COS7 cells were also cotransfected with the expression vectors pCMV-HKR127(III)HC and pKC-dhfr-HKR127, and the culture supernatant of transfected cells was used to characterize a humanized antibody HZKR127III.

15

This invention further provides pharmaceutical compositions containing said humanized antibody.

According to still other preferred embodiments, it was verified that HZKR127I and HZKR127III humanized antibodies of the present invention, showed almost same antigen-binding affinity when compared with mouse monoclonal antibody KR127 (see Table 1, 2 and FIG 6a, 6b).

The composition includes a therapeutically effective amounts of the humanized antibody against HBV antigen pre-S1, with/without a pharmaceutically acceptable delivery vehicle. Moreover, the

compositions may include other anti-hepatitis drug(s), such as anti-S monoclonal antibody or lamivudin.

5 The humanized antibody against HBV antigen pre-S1 may be formulated with a pharmaceutical vehicle or diluent for intravenous, subcutaneous, intramuscular administration. The pharmaceutical composition can be formulated in a classical manner using solid or liquid vehicles, diluents and additives appropriate to the desired mode of administration.

10 The humanized antibody of this invention may be administered in a dosage range of about 1 ~ 10 mg/kg, preferably 3 ~ 5 mg/kg, and may be administered once a week.

15

#### EXAMPLES

Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.

20 However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.

Example 1: Preparation of gene encoding humanized heavy chain

In order to construct the humanized heavy chain variable region gene, first, we selected a human immunoglobulin heavy chain gene that shows the highest homology of amino acid sequence to the heavy chain variable region of the mouse monoclonal antibody KR127. As the result, a human immunoglobulin germ line gene DP7 was selected from GenBank database. Then, we constructed a humanized V<sub>H</sub> region gene HKR127HCv(HZII) by DNA recombination techniques, which was based upon the comparison of the mouse KR127 V<sub>H</sub> region with the human DP7 V<sub>H</sub> region. Since the humanized heavy chain did not show significant antigen binding activity, we prepared HKR127HCv(HZI) gene encoding another V<sub>H</sub> region in order to improve the HKR127HCv(HZII) gene (see FIG 1).

Particularly, the HKR127HCv(HZII) gene was constructed by grafting the V<sub>H</sub> region of human DP7 gene with the partial CDR1, 2, and 3 and one FR residue at position 72 of mouse KR127 V<sub>H</sub> region. It was assumed that the human CDRs and FR amino acid residues affected the antigen-binding affinity of the antibody.

Therefore, HKR127HCv(HZI) gene was constructed by PCR employing HKR127HCv(HZII) gene as a template.

On the other hand, a vector pRc/CMV-HC-HuS (Accession Number: KCTC 0229BP) was used to synthesize DNA sequence encoding human C<sub>H</sub> region as well as heavy chain leader sequence, which is required in proper  
5 secretion of the heavy chain.

Finally, HKR127HC(I) gene encoding a humanized heavy chain was constructed by recombinant PCR for the annealing of the heavy chain leader sequence, HKR127HCv(HZI) gene, and the human C<sub>H</sub> gene (see FIG 2a).  
10 The primers in these PCRs are synthetic oligonucleotides described by SEQ ID NO: 1 to 12. PCR was performed by using Taq DNA polymerase, and its thermocycle was repeated 30 times, consisting of 1 minute at 94°C, 1 minute at 55°C, and then 1 minute at  
15 72°C. Five pairs of oligonucleotides (SEQ ID NO: 1 and 2; 3 and 4; 5 and 6; 7 and 8; and 9 and 10) were used as PCR primers, and the five PCR products (113 bp; 96 bp; 120 bp; 78 bp; and 87 bp, respectively) were brought to annealing reaction. Then, the DNA fragments  
20 containing the five PCR products were employed as template of the recombinant PCR wherein primers described by SEQ ID NO: 1 and 10 were used. Another recombinant PCR was conducted to link the amplified 431-bp DNA fragment to 1015-bp DNA fragment which was  
25 obtained by PCR using two primers (described by SEQ ID NO: 11 and 12). The recombinant PCR employed two primers described by SEQ ID NO: 1 and 12.

The final PCR product (HKR127HC(I), about 1431-bp) encoding a recombinant heavy chain of humanized antibody was introduced into the EcoRI-SalI site of pBluescript SK(+) vector (Clontech), and the resulting  
5 vector was designated pHKR127HC(I). The DNA sequence of the inserted gene was determined by dideoxynucleotide method.

To more humanize the HKR127HC(I), another humanized heavy chain gene, HKR127(III), which has much  
10 less number of mouse FR residues, was constructed.

To construct the HKR127HC(III), HKR127HCv(HZIII) gene was constructed by PCR employing HKR127HCv(HZII) gene as a template. On the other hand, a vector pRc/CMV-HC-HuS (Accession Number: KCTC 0229BP) was used  
15 to synthesize DNA sequence encoding human C<sub>H</sub> region as well as heavy chain leader sequence, which is required in proper secretion of the heavy chain.

Finally, HKR127HC(III) gene encoding a humanized heavy chain was constructed by recombinant PCR for  
20 annealing of the heavy chain leader sequence, HKR127HCv(HZIII) gene, and the human C<sub>H</sub> gene (see FIG 2b).

The primers in these PCRs are synthetic oligonucleotides described by SEQ ID NO: 24 to 28. PCR  
25 was performed by using Taq DNA polymerase, and its thermocycle was repeated 30 times, consisting of 1 minute at 94°C, 1 minute at 55°C, and then 1 minute at

72°C. Three pairs of oligonucleotides (SEQ ID NO: 1 and 24; 25 and 26; and 27 and 28) were used as PCR primers, and the three PCR products (179 bp; 141 bp; and 87 bp, respectively) were brought to annealing reaction. Then, the DNA fragments containing the three PCR products were employed as template of the recombinant PCR wherein primers described by SEQ ID NO: 1 and 28 were used. Another recombinant PCR was conducted to link the amplified 431-bp DNA fragment to 1015-bp DNA fragment which was obtained by PCR using two primers (described by SEQ ID NO: 11 and 12). The recombinant PCR employed two primers described by SEQ ID NO: 1 and 12.

The final PCR product (HKR127HC(III), about 1431-bp) encoding a recombinant heavy chain of humanized antibody was introduced into the EcoRI-SalI site of pBluescript SK(+) vector (Clontech), and the resulting vector was designated pHKR127HC(III). The DNA sequence of the inserted gene was determined by dideoxynucleotide method.

#### Example 2: Preparation of gene encoding humanized light chain

In order to prepare humanized light chain containing variable region, we devised genes encoding

the light chain. First, we selected a human  $\kappa$  immunoglobulin gene that shows the highest homology of amino acid sequence to the light chain of the mouse monoclonal antibody KR127. As the result, a human  $\kappa$  immunoglobulin gene DPK12 was selected from GenBank database. Then, we constructed HKR127KcV(HZII) gene encoding a humanized  $V_L$  region by grafting CDR1, partial CDR2, and CDR3 and one FR residue at position 41 of the mouse KR127  $V_L$  region to the human DPK12  $V_L$  region. The resulting humanized  $V_L$  was not functional in antigen-binding. To improve the HKR127KcV(HZII) gene, we constructed HKR127KcV(HZI) gene encoding another  $V_L$  region (see FIG 3).

The HKR127KcV(HZI) gene was constructed by grafting the  $V_L$  region of human DPK12 antibody with a few FR residues and CDR1, CDR2 and CDR3 of mouse KR127  $V_L$  (see FIG 3).

On the other hand, a vector pKC-dhfr-HuS (Accession Number: KCTC 0230BP) was used to synthesize DNA sequence encoding human  $C_L$  region as well as light chain leader sequence, which is required in proper secretion of the light chain.

Finally, HKR127Kc(I) gene encoding a humanized light chain was prepared by recombinant PCR for the annealing of the PCR products, light chain leader sequence, the HKR127KcV(HZI) gene, and the human  $C_L$  gene (see FIG 4).

The primers in these PCRs are synthetic oligonucleotides described by SEQ ID NO: 13 to 18. The thermocycle of these PCRs was repeated 30 times, consisting of 1 minute at 94°C, 1 minute at 55°C, and 1  
5 minute at 72°C. Two pairs of oligonucleotides (SEQ ID NO: 13 and 14; and SEQ ID NO: 15 and 16) were used as PCR primers, and the two PCR products (101 bp and 159 bp, respectively) were brought to annealing reaction. Then, the DNA fragments containing the two PCR products  
10 was employed as a template of recombinant PCR wherein primers described by SEQ ID NO: 13 and 16 were used. Another recombinant PCR was conducted to link the amplified 248-bp DNA fragment to 515-bp DNA fragment which was obtained by PCR using two primers (described  
15 by SEQ ID NO: 17 and 18). The recombinant PCR employed two primers described by SEQ ID NO: 13 and 18.

The final PCR product (HKR127KC(I), 736-bp) encoding a recombinant light chain of humanized antibody was introduced into the HindIII-SalI site of  
20 pBluescript SK(+) vector (Clontech), and the resulting vector was designated pHKR127KC(I). The DNA sequence of the inserted gene was determined by dideoxynucleotide method.



Example 3: Construction of expression vector containing  
the humanized heavy chain gene

The pHKR127HC(I) or pHKR127HC(III) plasmid of  
Example 1 was digested with SalI enzyme, and the both  
5 ends of the vector was made blunt using Klenow enzyme  
treatment. This DNA fragment was further digested with  
NotI enzyme to obtain the gene encoding humanized heavy  
chain.

On the other hand, pRc/CMV (Invitrogen) was cut  
10 with XbaI enzyme, and the ends of the vector was made  
blunt by treating with Klenow enzyme, and then digested  
with NotI.

The humanized heavy chain gene and the linearized  
vector were linked to give expression vector pCMV-  
15 HKR127HC or pCMV-HKR127(III)HC. The *E. coli*  
transformant containing pCMV-HKR127HC or pCMV-  
HKR127(III)HC was deposited in KCTC (Korean Collection  
for Type Culture) (Accession Number: KCTC 0531BP and  
KCTC 0691BP, respectively), and the expression vector  
20 pCMV-HKR127HC and pCMV-HKR127(III)HC is shown in FIG 5a  
and 5c, respectively.

Example 4: Construction of expression vector containing the humanized light chain gene

The pHKR127KC vector of Example 2 was digested with HindIII and ApaI enzymes, and the resulting  
5 fragment was inserted into HindIII-ApaI site of pCMV-dhfr (Accession Number: KCTC 8671P) to give expression vector pKC-dhfr-HKR127. The *E. coli* transformant containing pKC-dhfr-HKR127 was deposited in KCTC (Korean Collection for Type Culture) (Accession Number:  
10 KCTC 0529BP), and the expression vector pKC-dhfr-HKR127 is shown in FIG 5b.

Example 5: Expression of humanized antibody in COS7 cells

15 COS7 cells were maintained in DMEM (Gibco) supplemented by 10% calf serum at 37°C, under 5% CO<sub>2</sub> condition. The cells were inoculated in 100mm petri dishes, and then incubated at 37°C overnight.

To express a humanized antibody HZKR127I, 5 µg of  
20 pCMV-HKR127HC or pKC-dhfr-HKR127 was diluted with 800 µl of OPTI MEM I (Gibco), and 50 µl of Lipofectamin (Gibco) was also diluted with 800 µl of OPTI MEM I. These mixtures in 15-ml tubes were incubated at room temperature for 15 minutes or more. In the meantime,

COS7 cells were washed twice with OPTI MEM I.

OPTI MEM I (6.4 ml) was added to the DNA-Lipofectamin mixture, mixed well, and poured on the COS7 cells. After the cells were cultured in a CO<sub>2</sub> incubator for 72 hours, the medium was centrifuged, and the supernatant was concentrated by ultrafiltration kit. The concentration of antibody was determined by Sandwich ELISA using anti-human IgG and anti-human IgG-HRP (horseradish peroxidase) conjugate.

To express and obtain a humanized antibody HZKR127III, the same protocol was repeated except using pCMV-HKR127(III)HC instead of using pCMV-HKR127HC.

Example 6: Binding activity of humanized antibody to HBV surface antigen pre-S1

We prepared HBV surface antigen pre-S1 (amino acid residue 1-56; Kim and Hong, Biotechnology Letters, 17:871-876, 1995) and 1 µg of the purified pre-S1 was coated on each well in microplates. After addition of 0, 0.25, 0.5, 1, 2, 3, 4, 5, 7.5, 10, 20, or 40 ng of the humanized antibodies prepared in Example 5, indirect ELISA was performed, in which secondary antibody was Fc-specific anti-human IgG-HRP conjugate. The binding activities of the antibodies were determined by measuring OD at 492 nm.

Purified mouse KR127 antibody was used as a control, and ELISA of KR127 antibody was conducted using Fc-specific anti-mouse IgG-HRP conjugate as a secondary antibody. The result is presented in Table 1 and 2.

Table 1.

Binding activity of KR127 and HZKR127I to HBV surface antigen pre-S1 (OD at 492 nm)

Amount (ng) Antibody	0	0.25	0.5	1	2	3	4	5	7.5	10	20	40
KR127	0.09	0.12	0.15	0.20	0.30	0.36	0.43	0.54	0.60	0.80	1.16	1.64
HZKR127I	0.09	0.12	0.17	0.26	0.35	0.43	0.60	0.71	0.79	1.12	1.48	1.77

Table 2.

Binding activity of HZKR127I and HZKR127III to HBV surface antigen pre-S1 (OD at 492 nm)

Amount (ng) Antibody	0	0.25	0.5	1	2	3	4	5	7.5	10	20	40
HZKR127I	0.06	0.19	0.25	0.58	0.65	0.75	0.86	1.02	1.25	1.39	1.95	2.07
HZKR127III	0.06	0.20	0.37	0.60	0.87	1.10	1.24	1.37	1.65	1.89	2.04	2.10

Example 7: Antigen-binding affinity of humanized antibody to HBV surface antigen pre-S1

Antigen-binding affinity to HBV surface antigen

pre-S1 was assayed by competitive ELISA method(Ryu et al., J. Med. Virol., 52:226, 1997).

Binding reactions between the pre-S1 antigen ( $1 \times 10^{-7} \sim 1 \times 10^{-12}$  M) and the humanized antibody of Example 5 (5 ng), or between the antigen ( $1 \times 10^{-7} \sim 1 \times 10^{-12}$  M) and control antibody KR127 (5 ng), were performed at 37°C for 2 hours. Then the reaction mixtures were added to 96-well microplates coated with the 250 ng of antigen pre-S1.

FIG 6a shows the affinity of two kinds of antibodies. It was confirmed that the binding affinity of the humanized antibody HZKR127I is almost same as that of the mouse antibody KR127 ( $7 \times 10^7$  M<sup>-1</sup>).

FIG 6b shows the affinity of HZKR127III compared with that of HZKR127I. The affinity of HZKR127III ( $5 \times 10^7$  M<sup>-1</sup>) was not much different from that ( $7 \times 10^7$  M<sup>-1</sup>) of HZKR127I.

#### INDUSTRIAL APPLICABILITY

As shown above, the present invention provides humanized antibody against HBV surface antigen pre-S1, which shows similar level of binding affinity when compared with mouse monoclonal antibody, whereas immunogenicity of the humanized antibody is remarkably reduced. Thus, the humanized antibody of the present

invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.

Those skilled in the art will appreciate that the  
5 conceptions and specific embodiments disclosed in the  
foregoing description may be readily utilized as a  
basis for modifying or designing other embodiments for  
carrying out the same purposes of the present invention.  
Those skilled in the art will also appreciate that such  
10 equivalent embodiments do not depart from the spirit  
and scope of the invention as set forth in the appended  
claims.


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT  
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

## INTERNATIONAL FORM

## RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Hong Hyo-Jeong  
KIT Apt. 15-401, #237 Gajeong-dong, Yusong-ku, Taejon 305-350,  
Republic of Korea

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  <i>Escherichia coli</i> DH5 $\alpha$ /pCMV-HKR127HC	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  KCTC 0531BP
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on <b>October 12 1998</b>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____.	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Korean Collection for Type Cultures  Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):   PARK Yong-Ha, Director Date: October 17 1998


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT  
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

## INTERNATIONAL FORM

## RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: HONG, Hyo Jeong  
KIT Apt. 15 401, #237, Kajeong-dong, Yusong-ku, Taejeon 305-350,  
Republic of Korea

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  <i>Escherichia coli</i> DH5 $\alpha$ /pCMV-HKR127(III)HC	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  KCTC 0691BP
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on <b>November 15 1999</b> .	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Korean Collection for Type Cultures  Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejeon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: <b>November 18 1999</b>




## INTERNATIONAL FORM

## RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Hong Hyo-Jeong  
 KIT Apt. 15-401, #237 Gajeong-dong, Yusong-ku, Taejon 305-350,  
 Republic of Korea

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR:  <i>Escherichia coli</i> DH5 $\alpha$ /pKC-dhfr-BKR127	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  KCTC 0529BP
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on <b>October 12 1998</b>	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: Korean Collection for Type Cultures  Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  PARK Yong-Ha, Director Date: October 17 1998

**What is Claimed is**

1. A humanized antibody specific for HBV surface antigen pre-S1, containing humanized heavy and light chain variable regions
- 5 2. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 20
- 10 3. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 21
- 15 4. The humanized antibody of claim 1, wherein the humanized heavy chain variable region comprises an amino acid sequence which is modified from an amino acid residue of SEQ ID NO: 21 by at least one amino acid substitution selected from the group comprising  
20 Lys<sup>12</sup> → Val<sup>12</sup>, Thr<sup>28</sup> → Ala<sup>28</sup>, Thr<sup>30</sup> → Ser<sup>30</sup>,  
Met<sup>48</sup> → Ile<sup>48</sup>, Arg<sup>67</sup> → Lys<sup>67</sup>, Val<sup>68</sup> → Ala<sup>68</sup>,  
Met<sup>70</sup> → Leu<sup>70</sup>, Val<sup>79</sup> → Ala<sup>79</sup>, and Tyr<sup>95</sup> → Phe<sup>95</sup>
- 25 5. The humanized antibody of claim 1, wherein the humanized light chain variable region comprises amino acid sequence described by SEQ ID NO: 23

6. A gene encoding humanized heavy chain which contains a humanized heavy chain variable region of claim 2, 3 or 4
- 5
7. The gene of claim 6, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 20
- 10
8. The gene of claim 6, wherein the humanized heavy chain variable region comprises amino acid sequence described by SEQ ID NO: 21
- 15
9. A gene encoding humanized light chain which contains a humanized light chain variable region comprising amino acid sequence described by SEQ ID NO: 23
- 20
10. An expression vector containing the gene of claim 6
11. The expression vector of claim 10, pCMV-HKR127HC, wherein the gene of claim 7 is inserted into pRC/CMV (Accession Number: KCTC 0531BP)
- 25
12. The expression vector of claim 10, pCMV-HKR127(III)HC, wherein the gene of claim 8 is

inserted into pRC/CMV (Accession Number: KCTC  
0691BP)

13. An expression vector containing the gene of claim  
5 9

14. The expression vector of claim 13, pKC-dhfr-HKR127,  
wherein the gene of claim 9 is inserted into pCMV-  
dhfr (Accession Number: KCTC 0529BP)

10

15. Pharmaceutical composition containing the  
humanized antibody of claim 1, which may be  
administered in order to prevent HBV infection or  
to treat chronic hepatitis B

15

FIG. 1a

KR127VH	Q	V	Q	L	Q	Q	S	G	P	E	L	V	K	P	
DP7	CAG	GTC	CAG	CTG	CAG	CAG	TCT	GGA	CCT	GAA	CTG	GTG	AAG	CCT	42
HZII	CAG	GTG	CAG	CTG	GTG	CAG	TCT	GGG	GCT	GAG	GTG	AAG	AAG	CCT	
HZI	CAG	GTC	CAG	CTG	GTG	CAG	TCT	GGA	GCT	GAA	GTG	AAG	AAG	CCT	
HZIII	CAG	GTC	CAG	CTG	GTG	CAG	TCT	GGA	GCT	GAA	GTG	GTG	AAG	CCT	42
HZII	-	-	-	-	V	-	-	-	A	-	V	K	-	-	
HZI	-	-	-	-	V	-	-	-	A	-	V	-	-	-	
HZIII	-	-	-	-	V	-	-	-	A	-	V	K	-	-	
KR127VH	G	A	S	V	K	I	S	C	K	A	S	G	Y	A	
DP7	GGG	GCC	TCA	GTG	AAG	ATT	TCC	TGC	AAA	GCT	TCT	GGC	TAC	GCA	84
HZII	GGG	GCC	TCA	GTG	AAG	GTT	TCC	TGC	AAA	GCT	TCT	GGC	TAC	ACC	
HZI	GGG	GCC	TCA	GTG	AAG	GTT	TCC	TGC	AAA	GCT	TCT	GGC	TAC	GCA	
HZIII	GGG	GCC	TCA	GTG	AAG	GTT	TCC	TGC	AAA	GCT	TCT	GGC	TAC	ACC	84
HZII	-	-	-	-	-	V	-	-	-	-	-	-	-	T	
HZI	-	-	-	-	-	V	-	-	-	-	-	-	-	-	
HZIII	-	-	-	-	-	V	-	-	-	-	-	-	-	T	
KR127VH	F	S	S	S	W	M	N	W	V	K	Q	R	P	G	
DP7	TTC	AGT	AGT	TCT	TGG	ATG	AAC	TGG	GTG	AAG	CAG	AGG	CCT	GGA	126
HZII	TTC	ACC	AGC	TAC	TAT	ATG	CAC	TGG	GTG	CGA	CAG	GCC	CCT	GGA	
HZI	TTC	ACC	AGT	TAC	TGG	ATG	AAC	TGG	GTG	CGA	CAG	GCC	CCT	GGA	
HZIII	TTC	ACC	AGT	TCT	TGG	ATG	AAC	TGG	GTG	CGA	CAG	GCC	CCT	GGA	
HZII	-	T	-	Y	-	-	-	-	-	R	-	A	-	-	
HZI	-	-	-	-	-	-	-	-	-	R	-	A	-	-	
HZIII	-	T	-	-	-	-	-	-	-	R	-	A	-	-	
KR127VH	Q	G	L	E	W	I	G	R	I	Y	P	G	D	G	
DP7	CAG	GGT	CTT	GAG	TGG	ATT	GGA	CGG	ATT	TAT	CCT	GGA	GAT	GGA	168
HZII	CAA	GGG	CTT	GAG	TGG	ATG	GGA	ATA	ATC	AAC	CCT	AGT	GGT	GGT	
HZI	CAG	GGT	CTT	GAG	TGG	ATG	GGA	CGG	ATT	TAT	CCT	GGA	GAT	GGA	
HZIII	CAG	GGT	CTT	GAG	TGG	ATG	GGA	CGG	ATT	TAT	CCT	GGA	GAT	GGA	
HZII	-	-	-	-	-	M	-	-	-	-	-	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HZIII	-	-	-	-	-	M	-	-	-	-	-	-	-	-	
KR127VH	D	T	N	Y	N	G	K	F	K	G	K	A	T	L	
DP7	GAT	ACT	AAC	TAC	AAT	GGG	AAG	TTC	AAG	GGC	AAG	GCC	ACA	CTG	210
HZII	AGC	ACA	AGC	TAC	GCA	CAG	AAG	TTC	CAG	GGC	AGA	GTC	ACC	ATG	
HZI	GAT	ACT	AAC	TAC	GCA	CAG	AAG	TTC	CAG	GGC	AGA	GTC	ACA	ATG	
HZIII	GAT	ACT	AAC	TAC	GCA	CAG	AAG	TTC	CAG	GGC	AAG	GCC	ACA	CTG	
HZII	-	-	-	-	A	Q	-	-	Q	-	R	V	-	M	
HZI	-	-	-	-	A	Q	-	-	Q	-	-	-	-	-	
HZIII	-	-	-	-	A	Q	-	-	Q	-	R	V	-	M	

FIG. 1b

	T	A	D	K	S	S	S	T	A	Y	M	Q	L	S	
KR127VH	ACT	GCA	GAC	AAA	TCC	TCC	AGC	ACA	GCC	TAC	ATG	CAG	CTC	AGC	252
DP7	ACC	AGG	GAC	ACG	TCC	ACG	AGC	ACA	GTC	TAC	ATG	GAG	CTG	AGC	
HZII	ACT	GCA	GAC	ACG	TCC	ACG	AGC	ACA	GTC	TAC	ATG	GAG	CTC	AGC	
HZI	ACC	GCA	GAC	AAA	TCC	ACG	AGC	ACA	GCC	TAC	ATG	GAG	CTG	AGC	
HZIII	ACT	GCA	GAC	AAA	TCC	ACG	AGC	ACA	GTC	TAC	ATG	GAG	CTC	AGC	
HZII	-	-	-	T	-	T	-	-	V	-	-	E	-	-	
HZI	-	-	-	-	-	T	-	-	-	-	-	E	-	-	
HZIII	-	-	-	-	-	T	-	-	V	-	-	E	-	-	
	S	L	T	S	V	D	S	A	V	Y	F	C	A	R	
KR127VH	AGC	CTG	ACC	TCT	GTG	GAC	TCT	GCG	GTC	TAT	TTC	TGT	GCA	AGA	294
DP7	AGC	CTG	AGA	TCT	GAG	GAC	ACG	GCC	GTG	TAT	TAC	TGT	GCG	AGA	
HZII	AGC	CTG	AGA	TCT	GAG	GAC	ACG	GCG	GTC	TAT	TAC	TGT	GCA	AGA	
HZI	AGC	CTG	AGA	TCT	GAG	GAC	ACG	GCG	GTC	TAT	TTC	TGT	GCA	AGA	
HZIII	AGC	CTG	AGA	TCT	GAG	GAC	ACG	GCG	GTC	TAT	TAC	TGT	GCA	AGA	
HZII	-	-	R	-	E	-	T	-	-	-	Y	-	-	-	
HZI	-	-	R	-	E	-	T	-	-	-	-	-	-	-	
HZIII	-	-	R	-	E	-	T	-	-	-	Y	-	-	-	
	E	Y	D	E	A	Y	W	G	Q	G	T	L	V	T	
KR127VH	GAG	TAC	GAC	GAG	GCT	TAC	TGG	GGC	CAA	GGG	ACT	CTG	GTC	ACT	336
HZII	GAG	TAC	GAC	GAG	GAC	TAC	TGG	GGC	CAA	GGG	ACT	CTG	GTC	ACT	
HZI	GAG	TAC	GAC	GAG	GCT	TAC	TGG	GGC	CAA	GGG	ACT	CTG	GTC	ACT	
HZIII	GAG	TAC	GAC	GAG	GCT	TAC	TGG	GGC	CAA	GGG	ACT	CTG	GTC	ACT	
HZII	-	-	-	-	D	-	-	-	-	-	-	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HZIII	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	V	S	A												
KR127VH	GTC	TCT	GCA												345
HZII	GTC	TCT	TCA												
HZI	GTC	TCT	TCA												
HZIII	GTC	TCT	TCA												
HZII	-	-	S												
HZI	-	-	S												
HZIII	-	-	S												

FIG. 2a




FIG. 2b






FIG. 3a

	D	I	L	M	T	Q	T	P	L	I	L	S	V	T	
KR127VK	GAT	ATC	TTG	ATG	ACC	CAA	ACT	CCA	CTT	ATT	TTG	TCG	GTT	ACC	42
DPK12	GAT	ATT	GTG	ATG	ACC	CAG	ACT	CCA	CTC	TCT	CTG	TCC	GTC	ACC	
HZII	GAT	ATC	GTG	ATG	ACC	CAA	ACT	CCA	CTT	TCT	TTG	TCG	GTT	ACC	
HZII	-	-	V	-	-	-	-	-	-	S	-	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	S	-	-	-	-	
	I	G	Q	P	A	S	I	S	C	K	S	S	Q	S	
KR127VK	ATT	GGA	CAA	CCA	GCC	TCT	ATC	TCT	TGC	AAG	TCA	AGT	CAG	AGC	84
DPK12	CCT	GGA	CAG	CCG	GCC	TCC	ATC	TCC	TGC	AAG	TCT	AGT	CAG	AGC	
HZII	CCT	GGA	CAA	CCA	GCC	TCT	ATC	TCT	TGC	AAG	TCA	AGT	CAG	AGC	
HZII	P	-	-	-	-	-	-	-	-	-	-	-	-	-	
HZI	P	-	-	-	-	-	-	-	-	-	-	-	-	-	
	L	L	Y	S	N	G	K	T	Y	L	N	W	L	L	
KR127VK	CTC	TTA	TAT	AGT	AAT	GGA	AAA	ACC	TAT	TTG	AAT	TGG	TTA	TTA	126
DPK12	CTC	CTG	CAT	AGT	GAT	GGA	AAG	ACC	TAT	TTG	TAT	TGG	TAC	CTG	
HZII	CTC	TTA	TAT	AGT	AAT	GGA	AAA	ACC	TAT	TTG	AAT	TGG	TTA	TTA	
HZII	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Q	R	P	G	Q	S	P	K	R	L	I	Y	L	V	
KR127VK	CAG	AGG	CCA	GGC	CAG	TCT	CCA	AAG	CGC	CTA	ATC	TAT	CTG	GTG	168
DPK12	CAG	AAG	CCA	GGC	CAG	CCT	CCA	CAG	CTC	CTG	ATC	TAT	GAA	GTT	
HZII	CAG	AAG	CCA	GGC	CAG	CCT	CCA	CAG	CTC	CTA	ATC	TAT	CTG	GTG	
HZII	-	K	-	-	-	P	-	Q	L	-	-	-	-	-	
HZI	-	K	-	-	-	-	-	-	-	-	-	-	-	-	
	S	K	L	D	S	G	V	P	D	R	F	T	G	S	
KR127VK	TCT	AAA	CTG	GAC	TCT	GGA	GTC	CCT	GAC	AGG	TTC	ACT	GGC	AGT	210
DPK12	TCC	AAC	CGG	TTC	TCT	GGA	GTG	CCA	GAT	AGG	TTC	AGT	GGC	AGC	
HZII	TCT	AAA	CGG	TTC	TCT	GGA	GTC	CCT	GAC	AGG	TTC	AGT	GGC	AGT	
HZII	-	-	R	F	-	-	-	-	-	-	-	S	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	-	S	-	-	

FIG. 3b

	G	S	G	T	D	F	T	L	K	I	I	R	V	E	
KR127VK	GGA	TCA	GGA	ACA	GAT	TTT	ACA	CTG	AAA	ATC	ATC	AGA	GTG	GAG	252
DPK12	GGG	TCA	GGG	ACA	GAT	TTC	ACA	CTG	AAA	ATC	AGC	CGG	GTG	GAG	
HZII	GGA	TCA	GGA	ACA	GAT	TTT	ACA	CTG	AAA	ATC	AGC	AGA	GTG	GAG	
HZII	-	-	-	-	-	-	-	-	-	-	S	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	S	-	-	-	
	A	E	D	L	G	V	Y	Y	C	V	Q	G	T	H	
KR127VK	GCT	GAG	GAT	TTG	GGA	GTT	TAT	TAC	TGC	GTG	CAA	GGT	ACA	CAT	294
DPK12	GCT	GAG	GAT	GTT	GGG	GTT	TAT	TAC	TGC	ATG	CAA	AGT	ATA	CAG	
HZII	GCT	GAG	GAT	GTT	GGA	GTT	TAT	TAC	TGC	GTG	CAA	GGT	ACA	CAT	
HZII	-	-	-	V	-	-	-	-	-	-	-	-	-	-	
HZI	-	-	-	V	-	-	-	-	-	-	-	-	-	-	
	F	P	Q	T	F	G	G	G	T	K	L	E	I	K	
KR127VK	TTT	CCT	CAG	ACG	TTC	GGT	GGA	GGC	ACC	AAG	CTG	GAA	ATC	AAA	336
DPK12	CTT	CCT	CC												
HZII	TTT	CCT	CAG	ACG	TTC	GGT	GGA	GGC	ACC	AAG	GTG	GAA	ATC	AAA	
HZII	-	-	-	-	-	-	-	-	-	-	V	-	-	-	
HZI	-	-	-	-	-	-	-	-	-	-	V	-	-	-	
	R														
KR127VK	CGG														339
HZII	CGG														
HZII	-														
HZI	-														

FIG. 4




FIG. 5a




FIG. 5b




FIG. 5c




FIG. 6a





FIG. 6b



## SEQUENCE LISTING

- <110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY  
KOREA GREEN CROSS CORPORATION
- <120> HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND  
PREPARATION METHOD THEREOF
- <130> 9FP0-11-03
- <150> KR 1998-49663
- <151> 1998-11-19
- <160> 28
- <170> KOPATIN 1.5
- <210> 1
- <211> 26
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> synthetic oligonucleotide primer 1
- <400> 1  
gagaattcac attcacgatg tacttg 26
- <210> 2
- <211> 27
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> synthetic oligonucleotide primer 2
- <400> 2  
ggccccaggc ttcaccactt cagctcc 27



<210> 3  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 3

<400> 3  
gtgaagcctg gggcctca

18

<210> 4  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 4

<400> 4  
agaactactg aatgcgtagc cagaagc

27

<210> 5  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 5

<400> 5  
gcattcagta gttcttgat gaactgg

27

<210> 6  
<211> 27  
<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 6

<400> 6

aatccgtcca atccactcaa gaccctg

27

<210> 7

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 7

<400> 7

tggattggac ggatttatcc t

21

<210> 8

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 8

<400> 8

ggatttgtct gcagtcagtg tggccttgcc ctggaactt

39

<210> 9

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 9

<400> 9  
actgcagaca aatccacgag cacagcctac atggagctc 39

<210> 10  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 10

<400> 10  
gtcgtactct cttgcacaga aatagaccgc cgt 33

<210> 11  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 11

<400> 11  
gcaagagagt acgacgaggc ttactggggc caa 33

<210> 12  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 12

<400> 12  
cggtcgactc atttaccgg agacag 26

<210> 13

<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 13

<400> 13  
caaagcttgg aagcaagatg gattca 26

<210> 14  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 14

<400> 14  
tggagtttgg gtcacaaaga tatccccaca ggtacc 36

<210> 15  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 15

<400> 15  
atgacccaaa ctccactttc ttgtcggtt acccctggac aaccagcc 48

<210> 16  
<211> 39  
<212> DNA  
<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 16

<400> 16

caccagatag attaggcgct ttggagactg gcctggctt

39

<210> 17

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 17

<400> 17

ctaattctatc tgggtgtctaa actggactct ggagtcacct

39

<210> 18

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 18

<400> 18

gaagtcgacc taacct

17

<210> 19

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of heavy chain in mouse KR127 antibody

<400> 19

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1

5

10

15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser  
                   20                  25                  30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile  
                   35                  40                  45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe  
                   50                  55                  60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr  
                   65                  70                  75                  80

Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys  
                   85                  90                  95

Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr  
                   100                  105                  110

Val Ser Ala  
                   115

<210> 20

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of humanized heavy chain HKR127HC(HZI)

<400> 20

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala  
                   1                  5                  10                  15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser  
                   20                  25                  30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile  
                   35                  40                  45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60

Gln Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys  
 85 90 95

Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr  
 100 105 110

Val Ser Ser  
 115

<210> 21

<211> 115

<212> PRT

<213> Artificial Sequence

<220>

<223> variable region of humanized heavy chain HKR127HC(HZIII)

<400> 21

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser  
 20 25 30

Trp Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60

Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr  
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95  
 Ala Arg Glu Tyr Asp Glu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr  
 100 105 110

Val Ser Ser  
 115

<210> 22  
 <211> 113  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> variable region of light chain in mouse KR127 antibody

<400> 22  
 Asp Ile Leu Met Thr Gln Thr Pro Leu Ile Leu Ser Val Thr Ile Gly  
 1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser  
 20 25 30

Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser  
 35 40 45

Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60

Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80

Ile Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Val Gln Gly  
 85 90 95

Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
 100 105 110

Arg



<210> 23  
 <211> 113  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> variable region of humanized light chain  
  
 <400> 23  
 Asp Ile Leu Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly  
 1 5 10 15  
 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser  
 20 25 30  
 Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser  
 35 40 45  
 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro  
 50 55 60  
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile  
 65 70 75 80  
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Val Gln Gly  
 85 90 95  
 Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys  
 100 105 110

Arg

<210> 24  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> synthetic oligonucleotide primer 24

<400> 24  
gttcatccaa gaactggtga aggtgta 27

<210> 25  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 25

<400> 25  
agttcttgga tgaactgggt gcgacga 27

<210> 26  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 26

<400> 26  
gctcgtggat ttgtctgcag tcattgt 27

<210> 27  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> synthetic oligonucleotide primer 27

<400> 27  
gacaaatcca cgagcacagt ctacatg 27

<210> 28

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide primer 28

<400> 28

gtcgtactct ctcgcacagt aatacac

27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR 99/00699

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C 07 K 16/28; C 12 N 15/13, 15/63; A 61 K 39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: C 07 K; C 12 N; A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIL DATABASE, Derwent Publications Ltd., London (GB), PAJ DATABASE, EPO PAJ Database, CA DATABASE, STN Karlsruhe (DE)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO 93/16192 A1 (THE WELLCOME FOUNDATION LIMITED) 19 August 1993 (19.08.93), pages 1-5,12-18; claims.	1,15 2-14
A	C.J.RYU et al. "A Humanized Anitbody with Specificity for Hepatitis B Surface Antigen", Hum. Antibod. Hybridomas, Vol. 7, No. 3, 1996, pages 113-122., totality.	1-15
A	C.J.RYU et al. "In Vitro Neutralization of Hepatitis B Virus by Monoclonal Antibodies Against the Viral Surface Antigen", Journal of Medical Virology, Vol. 52, 1997, pages 226-233, totality.	1-15

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

27 January 2000 (27.01.00)

Date of mailing of the international search report

29 March 2000 (29.03.00)

Name and mailing address of the ISA/AT  
Austrian Patent Office  
Kohlmarkt 8-10; A-1014 Vienna  
Facsimile No. 1/53424/200

Authorized officer

Weniger

Telephone No. 1/53424/341

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00699

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	A1	9316192	19-08-1993	AU	A1	34595/93	03-09-1993
				GB	A0	9202796	25-03-1992
				ZA	A	9300928	10-08-1994